August 24, 2012
Durham, NC - A $50,000 grant awarded to a Duke University researcher from the Liddy Shriver Sarcoma Initiative will help fund studies examining a pediatric cancer that strikes the soft tissue.
The grant was awarded to lead investigator, Corinne Linardic, MD, PhD, an associate professor of pediatrics and assistant professor of pharmacology and cancer biology at Duke. Linardic and colleagues, including Lisa Crose, PhD, a post-doctoral associate, study rhabdomyosarcoma (RMS)--the most prevalent and difficult-to-cure soft tissue sarcoma in children and young adults.
Linardic leads a research team that has identified key molecular pathways that are disordered in the cancer cells, and the group is working to exploit these pathways to identify new treatment strategies for RMS patients.
“We are excited to receive this grant, which will enable us to continue important work and perhaps, identify potential new avenues for therapeutic approaches,” Linardic said.
Sarcoma is a relatively rare malignancy that develops in connective tissue, nerves, cartilage, bone and blood vessels. The National Institutes of Health (NIH) estimates that approximately 14,000 people in the United States were diagnosed with sarcomas last year, with 5,400 deaths from the diseases.
The Liddy Shriver Sarcoma Initiative funds research that seeks to better understand, treat and cure sarcomas. The grant program is highly selective, and past recipients include the Dana Farber Cancer Institute, Johns Hopkins Medical School and Georgetown University.
“We are delighted to fund Dr. Linardic’s and Crose’s research study in rhabdomyosarcoma,” said Bruce and Beverly Shriver, co-founders of the Liddy Shriver Sarcoma Initiative. “We hope that their plan to identify pathway regulators important in this rare and dangerous cancer will be a basis for designing new mouse models and therapeutic approaches. We also hope that such results will be important stepping stones to finding a cure for this cancer.”